top of page
COMPUTATIONALLY GUIDED DEVELOPMENT OF RNA-BASED THERAPIES.

COMPUTATIONALLY GUIDED DEVELOPMENT OF RNA-BASED THERAPIES.

Unlocking Therapeutic Potential at the Convergence of Computation and RNA

SKIP THERAPEUTICS

ABOUT

Skip therapeutics

SKIP Therapeutics develops RNA-based therapies for rare genetic disorders and common diseases – utilizing a proprietary computational discovery engine to optimize target selection and therapeutic design.

We employ sequence-based molecules, called Antisense Oligonucleotides (ASO), to restore function of mutated genes in rare genetic disorders or to modify functionality of key genes in major disease pathways.

We employ sequence-based molecules, called Antisense Oligonucleotides (ASO), to restore function of mutated genes in rare genetic disorders or to modify functionality of key genes in major disease pathways.

Convergence of SKIP’s novel computational discovery engine alongside strong experimental capabilities form a unique venture in the landscape of RNA-based therapies.

Convergence of SKIP’s novel computational discovery engine alongside strong experimental capabilities form a unique venture in the landscape of RNA-based therapies.

Skip therapeutics
Antisense oligonucleotides (ASOs) are emerging as an important therapeutic modality that can be utilized to modulate gene function in the cell.  These molecules are designed to bind regulatory regions on the RNA through precise complementary base pairing and induce change in RNA-splicing, expression, and functionality. Strategies include:

TECHNOLOGY

Modulating RNA using ASOs

Antisense oligonucleotides (ASOs) are emerging as an important therapeutic modality that can be utilized to modulate gene function in the cell.  These molecules are designed to bind regulatory regions on the RNA through precise complementary base pairing and induce change in RNA-splicing, expression, and functionality. Strategies include:

Exclusion (skipping) of exons to overcome stop codon mutations.

Prevention of abnormal splicing caused by point mutations.

Elevation of gene expression through targeting RNA regulatory regions.

Modulation of isoform balance and creation of novel isoforms.

Control of gene function through manipulation of protein domains.

Modulating RNA using ASOs
TEAM
SKIP has created a computational platform, that identifies and evaluates potential ASO-based strategies to restore mutated gene’s function in rare genetic disorders, or to modify gene function in common disease pathways. Leveraging genomic and proteomic data and “learning from” the comprehensive landscape of known pathogenic mutations, our method can assess the functionality of new isoforms. High throughput of SKIPs computational engine enables large scale analysis of mutations from patient registries and organizations and identification of “treatable” patient-cohorts around the world.      
SKIP’s Computational Engine.

SKIP’s Computational Engine.

SKIP has created a computational platform, that identifies and evaluates potential ASO-based strategies to restore mutated gene’s function in rare genetic disorders, or to modify gene function in common disease pathways. Leveraging genomic and proteomic data and “learning from” the comprehensive landscape of known pathogenic mutations, our method can assess the functionality of new isoforms. High throughput of SKIPs computational engine enables large scale analysis of mutations from patient registries and organizations and identification of “treatable” patient-cohorts around the world.      

SKIP WORKFLOW

01

PATIENT MUTATIONS

PATIENT MUTATIONS
 

| Medical institutions
| Sequencing centers
| Patient organizations

02

COMPUTATIONAL TARGET  IDENTIFICATION

COMPUTATIONAL TARGET 
IDENTIFICATION

 

| Therapeutic design
| Solution ranking

03

EXPERIMENTAL EVALUATION

EXPERIMENTAL EVALUATION

 

| ASO identification
| Functional evaluation

04

TARGET DEVELOPMENT

TARGET DEVELOPMENT
 

| In-house

| Co-development
| Out licensing

ALGORITHM  REINFORCEMENT

ALGORITHM 
REINFORCEMENT

DRUG DEVELOPMENT PIPELINE

 DISCOVERY

Indication                                                          Approach                  Bioinformatic            Experimental           Pre-clinical           Clinical

Retinal disease

Retinal disease

Restore normal splicing

Retinal disease

Pulmonary disease

Pulmonary disease

Exon skipping

Pulmonary disease

Muscular Dystrophy

Muscular Dystrophy

Restore normal splicing

Muscular Dystrophy

Renal

Renal

Gene expression

Renal

CNS

CNS

Exon skipping

CNS
skip therapeutics team

TEAM

CORE MEMBERS

MEMBERS

Dr. Ariel Feiglin
  • LinkedIn

Dr. Ariel Feiglin

CSO & Co Founder

Dr. Yehezkel (Hezi) Sztainberg
  • LinkedIn

Dr. Yehezkel (Hezi) Sztainberg

Head of Biology

Dr. Ilana Buchumenski
  • LinkedIn

Dr. Ilana Buchumenski

Bioinformatician

Dr. Maya David Teitelbaum
  • LinkedIn

Dr. Maya David Teitelbaum

Senior Scientist

Dr. Hagit Porath
  • LinkedIn

Dr. Hagit Porath

Bioinformatician

SKiP therapeutics was founded by the FutuRx  incubator based on research performed at Bar Ilan University. The company is funded by Takeda ventures, JJDC - J&J innovations, OrbiMed Partners, LEAPS by Bayer and RMG with support from the Israeli Innovation Authority (IIA).  It benefits from expertise of its investors and leading researchers.

INVESTORS

SKiP therapeutics was founded by the FutuRx  incubator based on research performed at Bar Ilan University. The company is funded by Takeda ventures, JJDC - J&J innovations, OrbiMed Partners, LEAPS by Bayer and RMG with support from the Israeli Innovation Authority (IIA).

It benefits from expertise of its investors and leading researchers.

FUTURX
leaps
takeda
RMG GLOBAL TRADING
J&J INNOVATION
ISRAEK INNOVATION AUTHORITY
orbimed
Request demo
SKiP therapeutics

CONTACT US

Thanks for submitting!

Tel: +972-(0)8-955-3149

2, Ilan Ramon St 
Ness Ziona, 7403635 Israel

bottom of page